Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

被引：227

作者：

Goetz, Matthew P. ^{[1
]}

Sangkuhl, Katrin ^{[2
]}

Guchelaar, Henk-Jan ^{[3
]}

Schwab, Matthias ^{[4
,5
,6
]}

Province, Michael ^{[7
]}

Whirl-Carrillo, Michelle ^{[2
]}

Symmans, W. Fraser ^{[8
]}

McLeod, Howard L. ^{[9
]}

Ratain, Mark J. ^{[10
]}

Zembutsu, Hitoshi ^{[11
]}

Gaedigk, Andrea ^{[12
,13
]}

van Schaik, Ron H. ^{[14
,15
]}

Ingle, James N. ^{[1
]}

Caudle, Kelly E. ^{[16
]}

Klein, Teri E. ^{[2
]}

机构：

[1] Mayo Clin, Dept Oncol, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA

[2] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA

[3] Leiden Univ, Dept Clin Pharm & Toxicol, Med Ctr, Leiden, Netherlands

[4] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

[5] Univ Hosp, Dept Clin Pharmacol, Tubingen, Germany

[6] Univ Tubingen, Dept Biochem & Pharm, Tubingen, Germany

[7] Washington Univ, Sch Med, Div Stat Genom, St Louis, MO USA

[8] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[10] Univ Chicago, Ctr Personalized Therapeut, Chicago, IL 60637 USA

[11] Natl Canc Ctr, Div Human Genet, Res Inst, Tokyo, Japan

[12] Univ Missouri, Div Clin Pharmacol Toxicol & Therapeut Innovat, Childrens Mercy Kansas City, Kansas City, MO 64110 USA

[13] Univ Missouri, Dept Pediat, Kansas City, MO 64110 USA

[14] Erasmus MC, Int Expertctr Pharmacogenet, Dept Clin Chem, Rotterdam, Netherlands

[15] LKCH UMC Utrecht, Utrecht, Netherlands

[16] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2018年 / 103卷 / 05期

基金：

美国国家卫生研究院;

关键词：

BREAST-CANCER PATIENTS; ADJUVANT TAMOXIFEN; ESTROGEN-RECEPTOR; IN-VITRO; POSTMENOPAUSAL WOMEN; ACTIVE METABOLITE; CODEINE THERAPY; GENOTYPE; CYP2C19-ASTERISK-2; POLYMORPHISMS;

D O I：

10.1002/cpt.1007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.

引用

页码：770 / 777

页数：8

共 50 条

[31] CYP2D6 Polymorphisms and the impact on tamoxifen therapy
Beverage, Jacob N.
Sissung, Tristan M.
Sion, Amy M.
Danesi, Romano
Figg, William D.
JOURNAL OF PHARMACEUTICAL SCIENCES, 2007, 96 (09) : 2224 - 2231
[32] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2C19and Proton Pump Inhibitor Dosing
Lima, John J.
Thomas, Cameron D.
Barbarino, Julia
Desta, Zeruesenay
Van Driest, Sara L.
El Rouby, Nihal
Johnson, Julie A.
Cavallari, Larisa H.
Shakhnovich, Valentina
Thacker, David L.
Scott, Stuart A.
Schwab, Matthias
Uppugunduri, Chakradhara Rao S.
Formea, Christine M.
Franciosi, James P.
Sangkuhl, Katrin
Gaedigk, Andrea
Klein, Teri E.
Gammal, Roseann S.
Furuta, Takahisa
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (06) : 1417 - 1423
[33] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
Birdwell, K. A.
Decker, B.
Barbarino, J. M.
Peterson, J. F.
Stein, C. M.
Sadee, W.
Wang, D.
Vinks, A. A.
He, Y.
Swen, J. J.
Leeder, J. S.
van Schaik, R. H. N.
Thummel, K. E.
Klein, T. E.
Caudle, K. E.
MacPhee, I. A. M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (01) : 19 - 24
[34] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy (vol 102, pg 45, 2017)
Moriyama, B.
Obeng, A. O.
Barbarino, J.
Penzak, S.
Henning, S.
Scott, S.
Agundez, J.
Wingard, J.
McLeod, H.
Klein, T.
Cross, S.
Caudle, K.
Walsh, T.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (02) : 349 - 349
[35] Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
Lee, Craig R.
Luzum, Jasmine A.
Sangkuhl, Katrin
Gammal, Roseann S.
Sabatine, Marc S.
Stein, Charles Michael
Kisor, David F.
Limdi, Nita A.
Lee, Yee Ming
Scott, Stuart A.
Hulot, Jean-Sebastien
Roden, Dan M.
Gaedigk, Andrea
Caudle, Kelly E.
Klein, Teri E.
Johnson, Julie A.
Shuldiner, Alan R.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (05) : 959 - 967
[36] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype
Relling, M. V.
McDonagh, E. M.
Chang, T.
Caudle, K. E.
McLeod, H. L.
Haidar, C. E.
Klein, T.
Luzzatto, L.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (02) : 169 - 174
[37] CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance
Higgins, Michaela J.
Stearns, Vered
CURRENT ONCOLOGY REPORTS, 2010, 12 (01) : 7 - 15
[38] CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance
Michaela J. Higgins
Vered Stearns
Current Oncology Reports, 2010, 12 : 7 - 15
[39] Pharmacogenetics and drug therapy in psychiatry - The role of the CYP2D6 polymorphism
Vandel, P.
Talon, J. M.
Haffen, E.
Sechter, D.
CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (02) : 241 - 250
[40] How to Integrate CYP2D6 Phenoconversion into Clinical Pharmacogenetics: A Tutorial
Cicali, Emily J.
Elchynski, Amanda L.
Cook, Kelsey J.
Houder, John T.
Thomas, Cameron D.
Smith, D. Max
Elsey, Amanda
Johnson, Julie A.
Cavallari, Larisa H.
Wiisanen, Kristin
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (03) : 677 - 687

← 1 2 3 4 5 →